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Abstract
Transcriptomic imputation approaches combine eQTL reference panels with large-scale genotype 
data in order to test associations between disease and gene expression. These genic associations 
could elucidate signals in complex GWAS loci and may disentangle the role of different tissues in 
disease development. We use the largest eQTL reference panel for the dorso-lateral pre-frontal 
cortex (DLPFC) to create a set of gene expression predictors, and demonstrate their utility. We 
applied DLPFC and 12 GTEx-brain predictors to 40,299 schizophrenia cases and 65,264 matched 
controls for a large transcriptomic imputation study of schizophrenia. We identified 413 genic 
associations across 13 brain regions. Stepwise conditioning identified 67 non-MHC genes, of 
which 14 did not fall within previous GWAS loci. We identified 36 significantly enriched 
pathways, including hexosaminidase-A deficiency, and multiple porphyric disorder pathways. We 
investigated developmental expression patterns among the 67 non-MHC genes, and identified 
specific groups of pre- and post-natal expression.
Editorial summary:
This study uses gene expression predictors for dorso-lateral pre-frontal cortex and other brain 
regions to perform a transcriptomic imputation analysis of schizophrenia, identifying 413 genic 
associations across 13 brain regions and 36 significantly enriched pathways.
Introduction
Genome-wide association studies (GWAS) have yielded large lists of disease-associated loci. 
Progress in identifying the causal variants driving these associations, particularly for 
complex psychiatric disorders such as schizophrenia, has lagged much further behind. 
Interpreting associated variants and loci is therefore vital to understanding how genetic 
variation contributes to disease pathology. Expression Quantitative Trait Loci (eQTLs), 
which are responsible for a substantial proportion of gene expression variance, have been 
posited as a link between associated loci and disease susceptibility1-5, and have yielded 
results for a host of complex traits6-9. Consequently, numerous methods to identify and 
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interpret co-localization of eQTLs and GWAS loci have been developed10-13. However, 
these methods require simplifying assumptions about genetic architecture (i.e., one causal 
variant per GWAS locus) and/or linkage disequilibrium, may be underpowered or overly 
conservative, especially in the presence of allelic heterogeneity, and have not yet yielded 
substantial insights into disease biology.
Biologically relevant transcriptomic information can be extracted through detailed RNA-
sequencing, as recently described by the CommonMind Consortium14 (CMC) in a large 
cohort of genotyped individuals with schizophrenia and bipolar disorder14. These analyses 
however are underpowered to detect statistically significant differential expression of genes 
mapping at schizophrenia (SCZ) risk loci, due to the small effects predicted by GWAS, 
combined with the difficulty of obtaining adequate sample sizes of neurological tissues14, 
and do not necessarily identify all risk variation in GWAS loci. Transcriptomic imputation is 
an alternative approach that leverages large eQTL reference panels to bridge the gap 
between large-scale genotyping studies and biologically useful transcriptome studies15,16. 
Transcriptomic imputation approaches codify the relationships between genotype and gene 
expression in matched panels of individuals, then impute the genetic component of the 
transcriptome into large-scale genotype-only datasets, such as case-control GWAS cohorts, 
enabling investigation of disease-associated gene expression changes. This will allow us to 
study genes with modest effect sizes, likely representing a large proportion of genomic risk 
for psychiatric disorders14,17.
The large collection of dorso-lateral pre-frontal cortex (DLPFC) gene expression data 
collected by the CMC 14 affords us a unique opportunity to study and codify relationships 
between genotype and gene expression. Here, we present a novel set of gene expression 
predictor models, built using CMC DLPFC data14. We compare different regression 
approaches to building these models (including elastic net15, Bayesian sparse linear mixed 
models and ridge regression16, and using max eQTLs), and benchmark performance of these 
predictors against existing GTEx prediction models. We applied our CMC DLPFC 
predictors and 12 GTEx-derived neurological prediction models to predict gene expression 
in schizophrenia GWAS data, obtained through collaboration with the Psychiatric Genomics 
Consortium (PGC) schizophrenia working group, the “CLOZUK2” cohort, and the 
iPSYCH-GEMS schizophrenia working group. We identified 413 genome-wide significant 
genic associations with schizophrenia in our PGC+CLOZUK2 sample, constituting 67 
independent associations outside the MHC region. We demonstrated the relevance of these 
associations to schizophrenia etiopathology using gene set enrichment analysis, and by 
examining the effects of manipulation of these genes in mouse models. Finally, we 
investigated spatio-temporal expression of these genes using a developmental transcriptome 
dataset, and identified distinct spatio-temporal patterns of expression across our associated 
genes.
Results
Prediction Models based on CMC DLPFC expression
Using matched CMC genotype and gene expression data, we developed DLPFC genetically 
regulated gene expression (GREX) predictor models. We systematically compared four 
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approaches to building predictors15,16 within a cross-validation framework. Elastic net 
regression had a higher distribution of cross-validation R2 (RCV2) and higher mean RCV2 
values (Supplementary Figure 1, 2a) than all other methods. We therefore used elastic net 
regression to build our prediction models. We compared prediction models created using 
elastic net regression on SVA-corrected and uncorrected data14. The distribution of Rcv2 
values for the SVA-based models was significantly higher than for the un-corrected data14,18 
(ks-test; p < 2.2 × 10−16; Supplementary figure 1b,c). In total, 10,929 genes were predicted 
with elastic net cross-validation Rcv2 > 0.01 in the SVA-corrected data and were included in 
the final predictor database (mean Rcv2 = 0.076).
To test the predictive accuracy of the CMC-derived DLPFC models, and to benchmark this 
against existing GTEx-derived prediction models, GREX was calculated in an independent 
DLPFC RNA-sequencing dataset (the Religious Orders Study Memory and Ageing Project, 
ROSMAP19,20). We compared predicted GREX to measured ROSMAP gene expression for 
each gene (Replication R2, or RR2) for the CMC-derived DLPFC models and twelve GTEx-
derived brain tissue models15,21 (Figure 1, Supplementary Figure 2b). CMC-derived DLPFC 
models had higher average RR2 values (Mean RR2 = 0.056), more genes with RR2 > 0.01, 
and significantly higher overall distributions of RR2 values than any of the twelve GTEx 
models (ks-test, p < 2.2 × 10−16 across all analyses; Figure 1). Median RR2 values were 
significantly correlated with sample size of the original tissue set (rho = 0.92, p = 7.2 × 
10−6), the number of genes in the prediction model (rho = 0.9, p = 2.6 × 10−5), and the 
number of significant ‘eGenes’ in each tissue type (rho = 0.95, p = 5.5 × 10−7; Figure 1c). 
Notably, these correlations persist after removing obvious outliers (Figure 1c).
To estimate trans-ancestral prediction accuracy, GREX was calculated for 162 African-
American individuals and 280 European individuals from the NIMH Human Brain 
Collection Core (HBCC) dataset (Supplementary Figure 2c). RR2 values were higher on 
average in Europeans than African-Americans (average RR_EUR2 = 0.048, RR_AA2 = 0.040), 
but were significantly correlated between African-Americans and Europeans (rho = 0.78, p < 
2.2 × 10−16, Pearson test; Supplementary Figure 3).
Application of Transcriptomic Imputation to Schizophrenia
We used CMC DLPFC and 12 GTEx–derived brain tissue prediction models to impute 
GREX of 19,661 unique genes in cases and controls from the PGC-SCZ GWAS study22. 
Predicted expression levels were tested for association with schizophrenia. Additionally, we 
applied CMC and GTEx-derived prediction models to summary statistics from 11 PGC 
cohorts (for which raw genotypes were unavailable) and the CLOZUK2 cohort. Meta-
analysis was carried out across all PGC-SCZ and CLOZUK2 cohorts using an inverse-
variance based approach in METAL. Our final analysis included 40,299 cases and 65,264 
controls (Supplementary Figure 4a).
We identified 413 genome-wide significant associations, representing 256 genes in 13 
tissues (Figure 2a). The largest number of associations was detected in the CMC-DLPFC 
GREX data (Figure 2c; 49 genes outside the MHC, 69 genes overall). We sought replication 
of our CMC DLPFC SCZ-associations in an independent dataset of 4,133 cases and 24,788 
controls in collaboration with the iPSYCH-GEMS SCZ working group (Supplementary 
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Figure 4b). We tested for replication of all Bonferroni-significant genes identified in our 
CMC-DLPFC analysis. Twelve out of 100 genes replicated in the iPSYCH-GEMS data, 
significantly more than expected by chance (binomial test, p = 0.0043). Notably, 11/12 
replicating loci are previous GWAS loci, compared to 38/88 non-replicating loci. There was 
significant concordance between our discovery (PGC+CLOZUK2) and replication 
(iPSYCH-GEMS) samples; 72/100 genes have consistent direction of effect, including all 12 
replicating genes (binomial p = 1.258 × 10−5), and we found significant correlation of effect 
sizes (p = 1.784 × 10−4; rho = 0.036) and –log10 p-values (p = 1.073 × 10−5; rho = 0.043).
To identify the top independent associations within genomic regions, which include multiple 
associations for a single gene across tissues, or multiple nearby genes, we partitioned genic 
associations into 58 groups defined based on genomic proximity and applied stepwise 
forward conditional analysis within each group (Supplementary Table 1). In total, 67 non-
MHC genes remained genome-wide significant after conditioning (Table 1; Figure 2a,b). 
The largest signal was identified in the CMC-DLPFC GREX data (24 genes; Figure 2c), 
followed by the Putamen (7 genes). Nineteen out of 67 genes did not lie within 1 Mb of a 
previously genome-wide significant GWAS locus22 (shown in bold, Table 1); of these, 5/19 
genes were within 1 Mb of a locus which approached genome-wide significance (p < 5 × 
10−07). The remaining 14 genes all fall within nominally significant PGC-SCZ GWAS loci 
(p < 8 × 10−04), but did not reach genome-wide significance.
We compared our CMC-DLPFC prediXcan associations statistics to COLOC results from 
our recent study23,24. Briefly, COLOC tests for co-localization between GWAS loci and 
eQTL architecture. We calculated COLOC probabilities of no-colocalization (“PP3”) and 
colocalization (“PP4”); we consider PP4 > 0.5 to be significant evidence of colocalization25. 
We found a significant correlation between prediXcan p-values and PP4 values; rho = 0.35, 
p = 2.3 × 10-311. Thirty-one genes had ‘strong’ evidence of co-localization between GWAS 
loci and lead or conditional eQTLs23; of these, 21 were genome-wide significant in our 
prediXcan analysis (significantly more than expected by chance, binomial p-value = 2.11 × 
10−104), and all had p < 1 × 10-4. We identified 40 GWAS loci with no significant prediXcan 
associations; all of these loci also had strong evidence for no co-localization in our COLOC 
analysis (median PP3 = 0.936, median PP4 = 0.0027).
Implicated genes highlight SCZ-associated molecular pathways
We tested for overlap between our non-MHC SCZ-associated genes and 8,657 genesets 
comprising 1) hypothesis-driven pathways and 2) general molecular database pathways. We 
corrected for multiple testing using the Benjamini-Hochberg false discovery rate (FDR) 
correction26.
We identified three significantly associated pathways in our hypothesis-driven analysis 
(Table 2). Targets of the fragile-X mental retardation protein formed the most enriched 
pathway (FMRP; p = 1.96 × 10−8). Loss of FMRP inhibits synaptic function, is comorbid 
with autism spectrum disorder, and causes intellectual disability, as well as psychiatric 
symptoms including anxiety, hyperactivity and social deficits27. Enrichment of this large 
group of genes has been observed frequently in studies of schizophrenia28,29 and 
autism27,30. There was a significant enrichment among our SCZ-associated genes and genes 
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that have been shown to be intolerant to loss-of-function mutations31 (p = 5.86 × 10−5) as 
well as with copy number variants (CNVs) associated with bipolar disorder32 (p = 7.92 × 
10−8), in line with a recent GWAS study of the same individuals29.
Next, we performed an agnostic search for overlap between our schizophrenia-associated 
genes and ~ 8,500 molecular pathways collated from large, publicly available databases. 
Thirty-three pathways were significantly enriched after FDR correction (Table 2, Suppl. 
Table 2), including a number of pathways with some prior literature in psychiatric disease. 
We identified an enrichment with porphyrin metabolism (p = 1.03 × 10−4). Deficiencies in 
porphyrin metabolism lead to “Porphyria”, an adult-onset metabolic disorder with a host of 
associated psychiatric symptoms, in particular episodes of violence and psychosis33-38. Five 
pathways potentially related to porphyrin metabolism, regarding abnormal iron level in the 
spleen, liver and kidney are also significantly enriched, including 2/5 of the most highly 
enriched pathways (p < 2.0 × 10−4). The PANTHER and REACTOME pathways for Heme 
biosynthesis and the GO pathway for protoporphyrinogen IX metabolic process, which are 
implicated in the development of porphyric disorders, are also highly enriched (p = 2.2 × 
10−4, 2.6 × 10−4, 4.1 × 10−4), although do not pass FDR-correction.
Hexosaminidase activity was enriched (p = 3.47 × 10−5) in our results; this enrichment is not 
driven by a single highly-associated gene; rather, every single gene in the HEX-A pathway is 
nominally significant in the SCZ association analysis (Supplementary Table 2). Deficiency 
of hexosaminidase A (HEX-A) results in serious neurological and mental problems, most 
commonly presenting in infants as “Tay-Sachs” disease39. Adult-onset HEX-A deficiency 
presents with neurological and psychiatric symptoms, notably including onset of psychosis 
and schizophrenia40. Five pathways corresponding to Ras- and Rab- signaling, protein 
regulation and GTPase activity were enriched (p < 6 × 10−5). These pathways have a crucial 
role in neuron cell differentiation41 and migration42, and have been implicated in the 
development of schizophrenia and autism43-46. We also find significant enrichment with 
protein phosphatase type 2A regulator activity (p = 5.24 × 10−5), which was associated with 
major depressive disorder (MDD) and across MDD, bipolar disorder (BPD) and SCZ in the 
same large integrative analysis47, and has been implicated in antidepressant response and 
serotonergic neurotransmission48.
GREX associations are consistent with functional validation
To test the functional impact of our SCZ-associated predicted gene expression changes 
(GREX), we performed two in-silico analyses. First, we compared differentially expressed 
genes in the Fromer et al. CMC analysis to DLPFC prediXcan results; 76/460 are nominally 
significant in the DLPFC prediXcan analysis, significantly more than would be expected by 
chance (binomial test, p = 8.75 × 10−20). In particular, the Fromer et al. analysis highlighted 
six loci where expression levels of a single gene putatively affected schizophrenia risk. All 
six of these genes are nominally significant in our DLPFC analysis, and two (CLCN3 and 
FURIN) reach genome-wide significance. In the conditional analysis across all brain 
regions, one additional gene (SNX19) reaches genome-wide significance. The direction of 
effect for all six genes matches the direction of gene expression changes observed in the 
original CMC paper, indicating that gene expression estimated in the imputed transcriptome 
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reflects measured expression levels in brains of individuals with schizophrenia. Further, this 
observation is consistent with a model where the differential expression signature observed 
in CMC is caused by genetics rather than environment.
To understand the impact of altered expression of our 67 SCZ-associated genes, we 
performed an in-silico analysis of mouse mutants, by collating large, publicly available 
mouse databases49-52. We identified mutant mouse lines lacking expression of 37/67 of our 
SCZ-associated genes, and obtained 5,333 phenotypic data points relating to these lines, 
including 1,170 related to behavioral, neurological or craniofacial phenotypes. Twenty-five 
out of 37 genes were associated with at least one behavioral, neurological or related 
phenotype (Supplementary Table 3).
We carried out two tests to assess the rate of phenotypic abnormalities in SCZ-associated 
mouse lines. First, we compared the proportion of SCZ-gene lines with phenotypic 
abnormalities to the ‘baseline’ proportion across all mouse lines for which we had available 
data. SCZ-associated lines were significantly more likely to display any phenotype (paired t-
test, p = 0.009647). Next, we repeated this analysis for genes identified in S-PrediXcan 
analyses of 66 publicly available GWAS datasets. SCZ mouse lines had higher levels of 
nervous system (40.5% vs. 37.6%), behavioral (35.1% vs. 32.0%), and eye/vision 
phenotypes (29.7% vs. 17.0%) compared to these ‘baseline’ GWAS comparisons. SCZ 
mouse lines also had higher rates of embryonic phenotypes, usually indicative of 
homozygous lethality or mutations incompatible with life (27.0% vs. 21.1%).
Distinct pattern of SCZ risk throughout development
We assessed expression of our SCZ-associated genes throughout development using 
BRAINSPAN53. Data were partitioned into eight developmental stages (four pre-natal, four 
post-natal), and four brain regions32,53 (Figure 3a). SCZ-associated genes were significantly 
co-expressed, in both pre-natal and post-natal development and in all four brain regions, 
based on local connectedness54 (Figure 3b), global connectedness54 (i.e., average path 
length between genes, Supplementary Figure 5), and network density (i.e., number of edges, 
Supplementary Figure 6). Examining pairwise gene expression correlation (Supplementary 
Figure 7) and gene co-expression networks (Supplementary Figure 8) for each 
spatiotemporal point indicated that the same genes do not drive this co-expression pattern 
throughout development; rather, it appears that separate groups of genes drive early pre-
natal, late pre-natal and post-natal clustering.
To visualize this, we calculated Z scores measuring the spatio-temporal specificity of gene 
expression for each SCZ-associated gene, across all 32 time-points (Figure 4). Genes 
clustered into four groups (Supplementary Figure 9), with distinct spatio-temporal 
expression signatures. The largest cluster (Cluster A, Figure 4a; 29 genes) spanned early to 
late-mid pre-natal development (4–24 weeks post conception (pcw)), either across the whole 
brain (22 genes) or in regions 1–3 only (7 genes). Twelve genes were expressed in late pre-
natal development (Figure 4d; 25–38 pcw); 10 genes were expressed in regions 1–3, post-
natally and in the late pre-natal period (Figure 4c), and 15 genes were expressed throughout 
development (Figure 4b), either specifically in region four (nine genes) or throughout the 
brain (six genes).
Huckins et al. Page 7
Nat Genet. Author manuscript; available in PMC 2020 February 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In order to probe the biological relevance of our four BRAINSPAN clusters, we compared 
these gene lists to known and candidate gene sets with relevance to schizophrenia55. Genes 
in clusters A and B, (i.e., clusters with pre-natal expression) were involved in brain 
morphology and development, nervous system development, neuron development and 
morphology and synaptic development, function, and morphology (Supplementary Table 4). 
These associations were not seen in clusters C and D (i.e., genes with late pre-natal and post-
natal expression).
We noticed a relationship between patterns of gene expression and the likelihood of 
behavioral, neurological or related phenotypes in our mutant mouse model database. Mutant 
mice lacking genes expressed exclusively pre-natally in humans, or genes expressed pre- and 
post-natally, were more likely to have any behavioral or neurological phenotypes than 
mutant mice lacking expression of genes expressed primarily in the third trimester or post-
natally (p = 1.7 × 10−4) (Supplementary Figure 10).
Discussion
In this study, we present DLPFC gene expression prediction models, constructed using 
CommonMind Consortium genotype and gene expression data. These prediction models 
may be applied to either raw data or summary statistics, in order to yield tissue-specific gene 
expression information in large data sets. This allows researchers to access transcriptome 
data for non-peripheral tissues, at scales currently prohibited by the high cost of RNA 
sequencing, and circumventing distortions in measures of gene expression stemming from 
errors of measurement or environmental influences. As disease status may alter gene 
expression but not the germline profile, analyzing genetically regulated expression ensures 
that we identify only the causal direction of effect between gene expression and disease15. 
Large, imputed transcriptomic datasets represent the first opportunity to study the role of 
subtle gene expression changes (and therefore modest effect sizes) in disease development.
There are some inherent limitations to this approach. The accuracy of transcriptomic 
imputation is reliant on access to large eQTL reference panels, and it is therefore vital that 
efforts to collect and analyze these samples continue. Transcriptomic inputation has exciting 
advantages for gene discovery as well as downstream applications15,56,57; however, the 
relative merits of existing methodologies are as yet under-explored. Here, sparser elastic net 
models better captured gene expression regulation than BSLMM; at the same time, the 
improved performance of elastic net over max-eQTL models suggests that a single eQTL 
model is over-simplified2,15. Fundamentally, transcriptomic imputation methods model only 
the genetically regulated portion of gene expression, and so cannot capture or interpret 
variance of expression induced by environment or lifestyle factors, which may be of 
particular importance in psychiatric disorders. Given the right study design, analyzing 
genetic components of expression together with observed expression could open doors to 
better study the role of gene expression in disease.
Sample size and tissue matching contribute to accuracy of transcriptomic imputation results. 
Our CMC-derived DLPFC prediction models had higher average validation R2 values in 
external DLPFC data than GTEx-derived brain tissue models. Notably, the model with the 
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second highest percent of genes passing the R2 threshold is the Thyroid, which has the 
largest sample size among the GTEx brain prediction models. When looking at mean R2 
values, the second highest value comes from the GTEx Frontal Cortex, despite the 
associated small sample size, implying at least some degree of tissue specificity of eQTLs 
architecture.
We compared transcriptomic imputation accuracy in European and African-American 
individuals, and found that our models were applicable to either ethnicity with only a small 
decrease in accuracy. Common SNPs shared across ethnicities have important effects on 
gene expression, and as such we expect GREX to have consistency across populations. 
There is a well-documented dearth of exploration of genetic associations in non-European 
cohorts58,59. We believe that these analyses should be carried out in non-European cohorts.
We applied the CMC-DLPFC and GTEx-derived prediction models to schizophrenia cases 
and controls from the PGC2 and CLOZUK2 collections, constituting a large transcriptomic 
analysis of schizophrenia. Predicted gene expression levels were calculated for 19,661 
unique genes across brain regions (Figure 1c) and tested for association with SCZ case-
control status. We identified 413 significant associations, constituting 67 independent 
associations. We found significant replication of our CMC DLPFC associations in a large 
independent replication cohort, in collaboration with the iPSYCH-GEMS consortium. Our 
prediXcan results were significantly correlated with co-localization estimates (“PP4”) from 
COLOC. Importantly, GWAS loci with no significant prediXcan associations also had no 
evidence for co-localization with eQTLs. Together, these results imply that our prediXcan 
associations identify genes with good evidence for colocalization between GWAS and eQTL 
architecture, and are not contaminated by linkage disequilibrium (LD). One caveat is that 
four of our associations (SNX19, NAGA, TYW5, and GNL3) have no evidence for 
colocalization in COLOC results, or following visual inspection of local GWAS and eQTL 
architecture, and may be false positives.
We compared our CMC DLPFC associations to results using a single-eQTL based method, 
SMR12, in the PGC+CLOZUK schizophrenia GWAS60, which identified 12 genome-wide 
significant associations. All significant SMR associations were also significant in our 
DLPFC prediXcan analysis, and all directions of effect were concordant between the two 
studies. A recent TWAS study of 30 GWAS summary statistic traits56 identified 38 non-
MHC genes associated at tissue-level significance with SCZ in CMC- and GTEx-derived 
brain tissues (i.e., matching those used in our study). Of these, 26 also reach genome-wide 
significance in our study, although in many instances these genes are not identified as the 
lead independent associated gene following our conditional analysis. Among our 67 SCZ-
associated genes, 19 were novel, i.e. did not fall within 1 Mb of a previous GWAS locus 
(including 5/7 of the novel brain genes identified in the recent TWAS analysis).
We used conditional analyses to identify independent associations within loci. These 
analyses clarify the most strongly associated genes and tissues (Table 1), while we note that 
nearly co-linear gene-tissue pairs could also represent causal associations. The tissues 
highlighted allowed us to tabulate apparently independent contributions to SCZ risk from 
different brain regions, even though their transcriptomes are highly correlated generally. We 
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find DLPFC and Cerebellum effects, as well as from Putamen, Caudate and Nucleus 
Accumbens Basal Ganglia. One caveat here is that tissue-associations are likely driven by 
sample size of the eQTL reference panel, as well as biology. It is likely that the large sample 
size of the DLPFC reference panel contributes partially to the greater signal identified in the 
DLPFC.
We used these genic associations to search for enrichments with molecular pathways and 
gene sets, and identified 36 significant enriched pathways. Among novel pathways, we 
identified a significant association with HEX-A deficiency. Despite the well-studied and 
documented symptomatic overlap between adult-onset HEX-A deficiency and 
schizophrenia, we believe that this is the first demonstration of shared genetics between the 
disorders. Notably, this overlap is not driven by a single highly-associated gene which is 
shared by both disorders; rather, every single gene in the HEX-A pathway is nominally 
significant in the SCZ association analysis, and five genes have p < 1 × 10−3, indicating that 
there may be substantial shared genetic etiology between the two disorders that warrants 
further investigation. Additionally, we identified a significant overlap between our SCZ-
associated genes and a number of pathways associated with porphyrin metabolism. 
Porphyric disorders have been well characterized and are among early descriptions of 
“schizophrenic” and psychotic presentations of schizophrenia, as described in the likely 
eponymous mid-19th century poem “Porphyria’s Lover”, by Robert Browning61, and have 
been cited as a likely diagnosis for the various psychiatric and metabolic ailments of Vincent 
van Gogh62-67 and King George III68.
Finally, we assessed patterns of expression for the 67 SCZ-associated genes throughout 
development using spatio-temporal transcriptomic data obtained from BRAINSPAN. We 
identified four clusters of genes, with expression in four distinct spatiotemporal regions, 
ranging from early pre-natal to strictly post-natal expression. There are plausible hypotheses 
and genetic evidence for SCZ disease development in adolescence, given the correlation 
with age of onset, as well as prenatally, supported by genetic overlap with 
neurodevelopmental disorders69-71 as well as the earlier onset of cognitive impairments72-75. 
Understanding the temporal expression patterns of SCZ-associated genes can help to 
elucidate gene development and trajectory, and inform research and analysis design. 
Identification of SCZ-associated genes primarily expressed prenatally is notable given our 
adult eQTL reference panels, and may reflect common eQTL architecture across 
development, which is known to be partial76-78; therefore, our results should spur interest in 
extending transcriptomic imputation data and/or methods to early development76. 
Identification of SCZ-associated genes primarily expressed in adolescence and adulthood is 
of particular interest for direct analysis of the brain transcriptome in adult psychiatric cases.
eQTL data have been recognized for nearly a decade as potentially important for 
understanding complex genetic variation. Nicolae et al.1 showed that common variant-
common disease associations are strongly enriched for genetic regulation of gene 
expression. Therefore, integrative approaches combining transcriptomic and genetic 
association data have great potential. Current transcriptomic imputation association analyses 
increase power for genetic discovery, with great potential for further development, including 
leveraging additional data types such as chromatin modifications79 (e.g. methylation, histone 
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modification), imputing different tissues or different exposures (e.g. age, smoking, trauma) 
and modeling trans/coexpression effects. It remains critical to leverage transcriptomic 
impuation associations to provide insights into specific disease mechanisms. Here, the 
accelerated identification of disease-associated genes allows the detection of novel pathways 
and distinct spatiotemporal patterns of expression in schizophrenia risk.
Online Methods (Limit 3,000 words, at end of manuscript, currently 2,064)
Creating gene expression predictors for the dorso-lateral pre-frontal cortex
eQTL Data—Genotype and RNAseq data were obtained for 538 European individuals 
through the CommonMind Project14. The mean age of these individuals was 67.4 years. 
RNA-seq data were generated from post-mortem human dorso-lateral prefrontal cortex 
(DLPFC). The gene expression matrix was normalized to log(counts per million) using 
voom. Adjustments were made for known covariates (including sample ascertainment, 
quality, experimental parameters, ancestry) and surrogate variables, using linear modelling 
with voom-derived regression weights. Details on genotyping, imputation and RNA-seq 
generation may be found in the CommonMind Consortium (CMC) flagship paper14.
The samples used here include 254 schizophrenia and 52 bipolar cases, as well as controls. 
The CMC flagship paper14 applied a permutation test and an explicit disease-genotype 
interaction term to demonstrate that there is no significant effect of disease on eQTLs. We 
have therefore included both cases and controls in this analysis, to maximize sample size.
A 1% minor allele frequency (MAF) cut-off was applied. Variants were filtered to remove 
any SNPs in high LD (r2>0.9), indels, and all variants with ambiguous ref/alt alleles. All 
protein coding genes on chromosomes 1–22 with at least one cis-SNP after these QC steps 
were included in this analysis (15,362 genes in total). SNPs in trans have been shown not to 
provide a substantial improvement in prediction accuracy15 and were not included here.
Building gene expression prediction databases
Gene expression prediction models were created following the “PrediXcan” method15. 
Matched genotype and gene expression data were used to identify a set of variants that 
influence gene expression (Supplementary Figure 2a). Weights for these variants are 
calculated using regression in a ten-fold cross-validation framework. All cross-validation 
folds were balanced for diagnoses, ethnicity, and other clinical variables.
All SNPs within the cis-region (+/− 1 Mb) of each gene were included in the regression 
analysis. Accuracy of prediction was estimated by comparing predicted expression to 
measured expression, across all 10 cross-validation folds; this correlation was termed cross-
validation R2 or Rcv2. Genes with Rcv2 > 0.01 (~p < 0.05) were included in our final 
predictor database.
Prediction models were compared across four different regression methods; elastic net 
(prediXcan), ridge regression (using the TWAS method16), Bayesian sparse linear mixed 
modelling (BSLMM; TWAS), and linear regression using the best eQTL for each gene 
(Supplementary Figure 1a). Mean Rcv2 values were significantly higher for elastic net 
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regression (mean Rcv2 = 0.056) than for eQTL-based prediction (mean Rcv2 = 0.025), 
BSLMM (mean Rcv2 = 0.021) or Ridge Regression (mean Rcv2 = 0.020). The distribution of 
Rcv2 values was also significantly higher for elastic net regression than for any other method 
(Kolgorov-Smirnov test, p < 2.2 × 10−16).
Replication of gene expression prediction models in independent data
Predictive accuracy of CMC DLPFC models were tested in two independent datasets.
First, we used data from the Religious Orders Study and Memory and Aging Project 
(ROSMAP19,20). This study included genotype data and DLPFC RNA-seq data for 451 
individuals of European descent (Supplementary Figure 2b).
DLPFC GREX was calculated using the CMC DLPFC predictor models. Correlation 
between RNA-seq expression and CMC DLPFC GREX (“Replication R2 values” or RR2) 
was used as a measure of predictive accuracy. RR2 was calculated including correction for 
ten ancestry components, as follows:
Equation 1: RR2 calculation.
RR1
2 = (M ∼ GREX + PC1 + PC2 +⋯ + PC10)
RR2
2 = (M ∼ PC1 + PC2 +⋯ + PC10)
RR
2 = RR1
2 ‐RR2
2
Where:
M Measured expression (RNA-seq)
GREX GREX imputed expression
PCn nth Principal Component
A small number of genes (158) had very low predictive accuracy and were removed from 
further analyses. Cross-validation R2 (Rcv2) values and RR2 values were highly correlated 
(rho = 0.62, p < 2.2 × 10−16; Supplementary Figure 3a). 55.7% of CMC DLPFC genes had 
RR2 values > 0.01.
Prediction accuracy was also assessed for 11 publicly available GTEx neurological predictor 
databases, and RR2 values used to compare to CMC DLPFC performance. CMC DLPFC 
models had higher average RR2 values, more genes with RR2 > 0.01, and significantly higher 
overall distributions of RR2 values than any of the twelve GTEx brain tissue models (ks-test, 
p < 2.2 × 10−16; Figure 1a,b).
To estimate trans-ancestral prediction accuracy, GREX was calculated for 162 African-
American individuals and 280 European individuals from the NIMH Human Brain 
Collection Core (HBCC) dataset (Supplementary Figure 2c). Predicted gene expression 
levels were compared to DLPFC expression levels measured using microarray. There was a 
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significant correlation between the European and African-American samples for RCV2 
values and RR2 values (rho = 0.66, 0.56; Supplementary Figure 3b,c). RR2 values were 
higher on average in Europeans, but were significantly correlated between African-
Americans and Europeans (rho = 0.78, p < 2.2 × 10−16, Pearson test; Supplementary Figure 
3d).
Extension to Summary Statistics
Transcriptomic Imputation may be applied to summary statistics instead of raw data, in 
instances where raw data is unavailable. However, this method suffers from slightly reduced 
accuracy, requires covariance matrices calculated in an ancestrally-matched reference 
population25 (usually only possible for European cohorts), and precludes testing of 
endophenotypes within the data, and so should not be applied when raw data are available.
We assessed concordance between CMC DLPFC transcriptomic imputation results using 
summary-statistics (S-PrediXcan25) and raw genotypes (PrediXcan15) using nine European 
and three Asian PGC-SCZ cohorts22 for which both data types were available. Cohorts were 
chosen to encompass a range of case : control ratios, to test previous suggestions that 
accuracy is reduced in unbalanced cohorts80. Covariances for all variants included in the 
DLPFC predictor models were computed using S-PrediXcan25. For all European cohorts, 
Pearson correlation of log-10 p-values and effect sizes was above 0.95. The mean correlation 
was 0.963 (Supplementary Figure 11).There was no correlation between total sample size, 
case-control ratio, p-value or effect-size. Seven genes were removed due to discordant p-
values. For the three Asian cohorts tested, the mean correlation was 0.91 (Supplementary 
Figure 12).
Concordance was also tested for the same nine European PGC-SCZ cohorts, across 12 
neurological GTEx prediction databases. All correlations were significant (rho > 0.95, p < 
2.2 × 10−16). There was a significant correlation between p-value concordance and case-
control ratio (rho = 0.37, p = 7.606 × 10−15). 114 genes had discordant p-values between the 
two methods and were excluded from future analyses.
Application to Schizophrenia
Dataset Collection—We obtained 53 discovery cohorts for this study, including 40,299 
SCZ cases and 65,264 controls (Supplementary Figure 4). 52/53 cohorts (35,079 cases, 
46,441 controls) were obtained through collaboration with the Psychiatric Genomics 
Consortium, and are described in the 2014 PGC Schizophrenia GWAS22. The remaining 
cohort, referred to as CLOZUK2, constitutes the largest single cohort of individuals with 
Schizophrenia (5,220 cases and 18,823 controls), collected as part of an effort to investigate 
treatment-resistant Schizophrenia60.
50/53 datasets included individuals of European ancestry, while three datasets include 
individuals of Asian ancestry (1,836 cases, 3,383 controls). All individuals were ancestrally 
matched to controls. Information on genotyping, quality control and other data management 
issues may be found in the original papers describing these collections22,60. All sample 
collections complied with ethical regulations. Details regarding ethical compliance and 
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consent procedures may be found in the original manuscripts describing these 
collections22,60.
Access to dosage data was available for 44/52 PGC-SCZ cohorts. The remaining PGC 
cohorts, and the CLOZUK2 cohort provided summary statistics. Three European PGC 
cohorts were trio-based, rather than case-control.
Additionally, we tested for replication of our CMC DLPFC associations in an independent 
dataset of 4,133 cases and 24,788 controls obtained through collaboration with the iPSYCH-
GEMS schizophrenia working group (effective sample size 14,169.5; Supplementary Figure 
4b, Supplementary Note).
Transcriptomic Imputation and association testing
Transcriptomic Imputation was carried out individually for each case-control PGC-SCZ 
cohort with available dosage data (44/52 cohorts). Predicted gene expression levels were 
computed using the DLPFC predictors described in this manuscript, as well as for 11 other 
brain tissues prediction databases created using GTEx tissues15,21,81,82 (Figure 1c). 
Associations between predicted gene expression values and case-control status were 
calculated using a linear regression test in R. Ten ancestry principal components were 
included as covariates. Association tests were carried out independently for each cohort, 
across 12 brain tissues.
For the eight PGC cohorts with no available dosage data, the three PGC trio-based analyses, 
and the CLOZUK2 cohort, a summary-statistic based transcriptomic imputation approach 
was used (“S-PrediXcan25”), as described previously.
Meta-analysis
Meta-analysis was carried out across all 53 cohorts using METAL83. Cochran’s Q test for 
heterogeneity was implemented in METAL83,84, and a heterogeneity p-value threshold of p 
> 1 × 10−3 applied to results. A conservative significance threshold was applied to these 
data, correcting for the total number of genes tested across all tissues (121,611 gene-region 
tests in total). This resulted in a genome-wide significance threshold of 4.1 × 10-7.
Effect sizes and direction of effect quoted in this manuscript refer to changes in predicted 
expression in cases compared to controls i.e., genes with negative effect sizes have decreased 
predicted expression in cases compared to controls.
Identifying independent associations
We identified a number of genomic regions which contained multiple gene associations 
and/or genes associated across multiple tissues. We identified 58 of these regions, excluding 
the MHC, based on distance between associated genes, and verified them using visual 
inspection. In order to identify independent genic associations within these regions, we 
carried out a stepwise forward conditional analysis following “GCTA-COJO” theory85 using 
“CoCo” (see URLs), an R implementation of GCTA-COJO. CoCo allows the specification 
of custom correlation matrices by the user (for example, ancestrally specific LD matrices). 
For each region, we generated a predicted gene expression correlation matrix for all 
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significant genes (p≤ 1×10−6), as the root-effective sample size83 (Neff, eqn 2) weighted 
average correlation across all cohorts where we had access to dosage data.
Equation 2: Effective Sample Size, Neff
Neff =
4
( 1Ncases
+ 1Ncontrols
)
Forward stepwise conditional analysis of all significant genes was carried out using joint 
linear regression modeling. First, the top-ranked gene was added to the model, then the next 
most significant gene in a joint model is added if significant at a given p-value threshold, and 
so on until either all genes are added to the model, or no joint statistic reaches the 
significance threshold.
We calculated effect sizes and odds ratios for SCZ-associated genes by adjusting “CoCo” 
betas to have unit variance (Table 1, eqn. 3).
Equation 3: GREX Beta adjustment
β = βCoCo x GVAR
Where GVAR is the variance of the GREX predictor for each gene.
Gene set Analyses
Pathway analyses were carried out using an extension to MAGMA86. P-values were 
assigned to genes using the most significant p-value achieved by each gene in the meta-
analysis. We then carried out a competitive gene-set analysis test using these p-values, using 
two gene sets:
1. 159 gene sets with prior hypotheses for involvement in SCZ development, 
including loss-of-function intolerant genes, CNV-intolerant genes, targets of the 
fragile-X mental retardation protein, CNS related gene sets, and 104 behavioral 
and neurological pathways from the Mouse Genome Informatics 
database14,60,69,87.
2. An agnostic analysis, including ~8,500 gene sets collated from publicly available 
databases including GO88,89, KEGG90, REACTOME91, PANTHER92,93, 
BIOCARTA94 and MGI52. Sets were filtered to include only gene sets with at 
least ten genes.
Significance levels were adjusted across all pathways included in either test using the 
Benjamini-Hochberg “FDR” correction in R26.
URLs
https://github.com/theboocock/coco/ “CoCo”, an R implementation of GCTA-COJO.
gene2pheno.org Publicly-available whole-blood-derived S-PrediXcan results (as of March 2018,)
https://github.com/laurahuckins/CMC_DLPFC_prediXcan Our CMC-derived DLPFC prediction models are publicly available at
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Coexpression of SCZ genes throughout development
We investigate spatiotemporal expression of our associated genes using publicly available 
developmental transcriptome data, obtained from the BRAINSPAN consortium53. We 
partitioned these data into biologically relevant spatio-temporal data sets95, corresponding to 
four general brain regions; the frontal cortex, temporal and parietal regions, sensory-motor 
regions, and subcortical regions (Figure 3a96), and eight developmental time-points (four 
pre-natal, four post-natal)95.
First, we tested for correlation of gene expression for all SCZ-associated genes at each 
spatiotemporal time-point. Genes with pearson correlation coefficients >= 0.8 or <=−0.8 
were considered co-expressed. 100,000 iterations of this analysis were carried out using 
random gene sets with equivalent expression level distributions to the SCZ-associated genes. 
For each gene set, a gene co-expression network was created, with edges connecting all co-
expressed genes. Networks were assessed using three criteria; first, the number of edges 
within the network, as a crude measured of connectedness; second, the Watts-Strogatz 
average path length between nodes, as a global measure of connectedness across all genes in 
the network54; third, the Watts-Strogatz clustering coefficient, to measure tightness of the 
clusters within the network54. For each spatio-temporal time point, we plotted gene-pair 
expression correlation (Supplementary Figure 7) and co-expression networks 
(Supplementary Figure 8).
For each of the 67 SCZ-associated genes, we calculated average expression at each 
spatiotemporal point. We then calculated Z-Score of expression specificity using these 
values, and plotted Z-Scores to visually examine patterns of gene expression throughout 
development and across brain regions. Clusters were formally identified using a dendrogram 
cut at height 10 (Supplementary Figure 9).
In-silico replication of SCZ-associated genes in mouse models
We downloaded genotype, knock-out allele information and phenotyping data for ~10,000 
mouse mutant models from five large mouse phenotyping and genotyping projects; Mouse 
Genome Informatics (MGI52), EuroPhenome49,97, Mouse Genome Project (MGP49,50), 
International Mouse Phenotyping Consortium (IMPC98), and Infection and Immunity 
Immunophenotyping (3I98). Where possible, we also downloaded raw phenotyping data 
regarding specific assays. In total, we obtained 175,012 phenotypic measurements, across 
10,288 mutant mouse models. We searched for any mouse lines with phenotypes related to 
behavior (natural, observed, stereotypic or assay-induced); cognition or working memory; 
brain, head or craniofacial dysmorphology; retinal or eye morphology, and/or vision or 
visual dysfunction or impairment; ear morphology or hearing dysfunction or impairment; 
neural tube defects; brain and/or nervous system development; abnormal nociception.
We calculated the rate of phenotypic abnormalities in all mouse lines with reduced 
expression of genes identified in our prediXcan analysis (“SCZ-associated mouse lines”). 
We compared these to (1) the ‘baseline’ rate of phenotypic abnormalities across all 10,288 
mouse lines; and (2) the rate of abnormalities in mouse lines associated with other disorders. 
To do this, we downloaded all publicly-available whole-blood-derived S-PrediXcan results 
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(as of March 2018, see URLs). In total, we obtained data for 1,907 genes reaching p < 5 × 
10−6, across 65 studies. We calculated rates of phenotypic abnormalities for each of these 65 
studies.
Data Availability
Our CMC-derived DLPFC prediction models are publicly available at https://github.com/
laurahuckins/CMC_DLPFC_prediXcan
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: Replication of DLPFC prediction models in independent data.
Measured gene expression (ROSMAP RNA-seq) was compared to predicted genetically-
regulated gene expression for CMC DLPFC and 12 GTeX predictor databases. Replication 
R2 values are significantly higher for the DLPFC than for the 12 GTEX brain expression 
models.
A. Distribution of RR2 values of CMC DLPFC predictors in ROSMAP data. Mean RR2 = 
0.056. 47.7% of genes have RR2 >= 0.01. Boxplots show mean, quartiles,; whiskers show 
full range of data.
B. Distribution of RR2 values of 12 GTeX predictors in ROSMAP data.
Table of sample sizes and p-val thresholds for CMC DLPFC and GTeX data. Number of 
samples, number of genes in the prediXcan model and number of eGenes are all 
significantly correlated with predictor performance in ROSMAP data (spearman correlation 
test).
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Figure 2: SCZ associations results
A) 413 genes are associated with SCZ across 12 brain tissues. Each point represents one 
gene-tissue pair.
B) 67 genes remain significant outside the MHC after stepwise conditional analysis
C) Number of genome-wide significant loci, outside the MHC region, identified in each 
brain region. These trends are partly driven by differences in power between brain regions.
Abbreviations are as follows; CB- Cerebellum; CX- Cortex; FL- Frontal Cortex; DLPFC- 
Dorso-lateral pre-frontal cortex; CB HEMI- Cerebellar Hemisphere; HIP- Hippocampus; 
PIT- Pituitary Gland; HTH- Hypothalamus; NAB- Nucleus Accumbens (Basal Ganglia); 
PUT- Putamen (Basal Ganglia); CAU- Caudate (Basal Ganglia); CNG- Anterior Cingulate 
Cortex
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Figure 3: SCZ-associated genes are co-expressed throughout development and across brain 
regions
A) Brain tissues selected for each of four brainspan regions. Brainspan includes 525 samples 
from 43 unique individuals. Region 1: IPC, V1C, ITC, OFC, STC, A1C; Region 2:S1C, 
M1C, DFC, VFC, MFC; Region 3:HIP, AMY, STR; Region 4: CB
Average clustering coefficients were calculated for all pairs of SCZ-associated genes, and 
compared to average clustering coefficients for 100,000 permuted gene networks to obtain 
empirical significance levels.
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Figure 4: Gene expression patterns for SCZ-associated genes cluster into four groups, relating to 
distinct spatiotemporal expression.
Brain regions are shown in figure 3a.
A. 29 genes are expressed in the early-mid pre-natal period (4-24 post-conception weeks)
B. 15 genes are expressed throughout development; subclusters correspond to either specific 
expression in region 4, or expression across the brain
C. Ten genes are expressed in the late-prenatal (25-38pcw) and post-natal period
D. 12 genes are expressed in the late pre-natal period (25-39pcw)
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Table 1:
SCZ-associated genes following conditional analysis.
67 non-MHC genes are significantly associated with schizophrenia following conditional analysis. Effect sizes 
(BETA) refer to predicted genetically regulated gene expression (GREX) in cases compared to controls. Effect 
sizes and odds ratios are also shown adjusted to ‘unit’ variance in gene expression. OR, odd’s ratio; DLPFC, 
dorso-lateral prefrontal cortex
Gene name Tissue BETA P GVAR
Adjusted
BETA
Adjusted
OR
GNL3 Cerebellum 0.037 1.39×10−11 0.115 0.012 1.012
THOC7 Cerebellum −0.113 5.77×10−10 0.010 −0.011 0.989
NAGA Cerebellum 0.122 1.12×10−09 0.009 0.011 1.011
TAC3 Cerebellum −0.868 8.03×10−08 0.000 −0.015 0.985
CHRNA2 Cerebellum −0.016 1.63×10−07 0.395 −0.010 0.990
ACTR5 Cerebellum 0.208 3.88×10−07 0.019 0.029 1.029
INO80E Frontal Cortex 0.130 7.25×10−12 0.009 0.012 1.013
PLPPR5 Frontal Cortex −0.672 2.58×10−09 0.006 −0.053 0.948
FAM205A Frontal Cortex 0.043 1.21×10−08 0.061 0.011 1.011
AC110781.3 Thyroid 0.342 1.31×10−13 0.002 0.014 1.014
IMMP2L Thyroid −0.073 7.09×10−12 0.046 −0.016 0.984
IGSF9B Thyroid −0.024 3.05×10−07 0.156 −0.010 0.991
NMRAL1 Thyroid 0.038 4.03×10−07 0.060 0.009 1.009
HIF1A DLPFC 11.130 7.52×10−14 0.000 0.148 1.159
TIMM29 DLPFC 11.207 9.27×10−14 0.000 0.168 1.183
ST7-OT4 DLPFC 10.170 5.79×10−13 0.001 0.318 1.374
H2AFY2 DLPFC 10.962 3.60×10−12 0.000 0.191 1.211
STARD3 DLPFC 10.740 5.90×10−12 0.001 0.304 1.355
CTC-471F3.5 DLPFC 8.535 1.11×10−11 0.000 0.104 1.110
SF3A1 DLPFC 8.651 1.32×10−11 0.000 0.083 1.086
ZNF512 DLPFC 10.312 1.32×10−11 0.001 0.261 1.298
FURIN DLPFC −0.084 2.22×10−11 0.022 −0.012 0.988
INHBA-AS1 DLPFC 8.399 2.24×10−11 0.000 0.127 1.135
SF3B1 DLPFC 0.099 6.14×10−11 0.014 0.012 1.012
EFTUD1P1 DLPFC −0.092 1.81×10−10 0.017 −0.012 0.988
MLH1 DLPFC 2.840 2.10×10−10 0.001 0.069 1.071
GATAD2A DLPFC −0.044 2.18×10−10 0.071 −0.012 0.988
METTL1 DLPFC 9.357 2.23×10−10 0.000 0.166 1.181
DMC1 DLPFC 7.229 4.48×10−10 0.000 0.130 1.139
RAD51D DLPFC 7.612 2.11×10−09 0.000 0.111 1.117
RERE DLPFC 2.847 6.32×10−09 0.000 0.036 1.037
PCCB DLPFC −0.044 2.05×10−08 0.054 −0.010 0.990
CLCN3 DLPFC 0.141 2.96×10−08 0.005 0.010 1.010
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Gene name Tissue BETA P GVAR
Adjusted
BETA
Adjusted
OR
ATG101 DLPFC 8.086 4.90×10−08 0.007 0.695 2.005
JRK DLPFC 0.032 1.25×10−07 0.091 0.010 1.010
PTPRU DLPFC −0.077 1.60×10−07 0.016 −0.010 0.990
MARCKS DLPFC 0.398 2.05×10−07 0.001 0.015 1.015
TCF4 Anterior Cingulate Cortex −0.059 5.22×10−13 0.051 −0.013 0.987
DGKD Anterior Cingulate Cortex −0.937 2.63×10−11 0.001 −0.022 0.979
C1QTNF4 Anterior Cingulate Cortex −0.173 1.37×10−09 0.010 −0.017 0.983
PITPNA Anterior Cingulate Cortex −0.243 1.77×10−07 0.002 −0.010 0.990
FXR1 Caudate Basal Ganglia 0.439 5.40×10−12 0.001 0.017 1.017
ZDHHC1 Caudate Basal Ganglia 0.354 5.36×10−08 0.001 0.011 1.012
PDE4D Cerebellar Hemisphere 0.365 6.81×10−11 0.001 0.013 1.013
DRD2 Cerebellar Hemisphere −0.182 2.47×10−10 0.004 −0.012 0.988
PITPNM2 Cerebellar Hemisphere −0.065 2.21×10−09 0.028 −0.011 0.989
RINT1 Cerebellar Hemisphere 0.086 6.32×10−09 0.016 0.011 1.011
SRMS Cerebellar Hemisphere −0.440 3.08×10−08 0.001 −0.011 0.989
SETD6 Cerebellar Hemisphere −0.043 1.05×10−07 0.054 −0.010 0.990
APOPT1 Cortex −0.074 1.24×10−10 0.026 −0.012 0.988
VSIG2 Cortex −0.092 6.01×10−09 0.013 −0.011 0.989
SDCCAG8 Cortex −0.069 3.88×10−07 0.002 −0.003 0.997
PIK3C2A Cortex −0.040 4.04×10−07 0.365 −0.024 0.976
AS3MT Frontal Cortex 0.594 5.65×10−17 0.001 0.017 1.017
FOXN2 Hippocampus −0.250 2.65×10−07 0.021 −0.036 0.964
RASIP1 Nucleus Accumbens Basal Ganglia 0.055 3.80×10−08 0.034 0.010 1.010
TCF23 Nucleus Accumbens Basal Ganglia −0.076 4.83×10−08 0.019 −0.010 0.990
TTC14 Nucleus Accumbens Basal Ganglia −0.089 4.84×10−08 0.013 −0.010 0.990
TYW5 Putamen Basal Ganglia −0.080 2.63×10−13 0.035 −0.015 0.985
SNX19 Putamen Basal Ganglia 0.031 1.31×10−12 0.179 0.013 1.013
CIART Putamen Basal Ganglia 0.090 6.78×10−10 0.017 0.012 1.012
SH2D7 Putamen Basal Ganglia 0.096 7.89×10−09 0.013 0.011 1.011
DGUOK Putamen Basal Ganglia 0.255 8.26×10−08 0.002 0.011 1.011
C12orf76 Putamen Basal Ganglia 0.031 2.27×10−07 0.095 0.010 1.010
LRRC37A Putamen Basal Ganglia −0.035 2.69×10−07 0.076 −0.010 0.991
AC005841.1 Pituitary 0.162 3.28×10−09 0.005 0.011 1.011
RPS17 Pituitary 0.035 4.03×10−08 0.082 0.010 1.010
Associations in the MHC region
BTN1A1 Caudate Basal Ganglia −0.261 1.67×10−22
VARS2 Anterior Cingulate Cortex 0.075 7.48×10−15
HIST1H3H Putamen Basal Ganglia −1.106 3.22×10−10
NUDT3 Nucleus Accumbens Basal Ganglia 0.104 6.55×10−9
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Table 2:
Significantly enriched pathways and gene sets.
We tested for enrichment of 8,657 pathways among our prediXcan results using a competitive p-value in 
MAGMA and calculated an FDR-corrected p-value to determine significance. FMRP, fragile-X mental 
retardation protein; BP, bipolar; CNV, copy number variant; LOF, loss of function.
Analysis Gene Set Comp P FDR P
Hypothesis driven FMRP-targets 1.96×10−08 3.097×10−06
BP denovo CNV 7.92×10−08 6.257×10−06
HIGH LOF intolerant 5.86×10−05 0.00309
Agnostic Increased spleen iron level 2.72×10−08 0.000245
Decreased IgM level 6.80×10−07 0.00307
Condensed chromosome 1.99×10−06 0.00598
Chromosome 2.80×10−06 0.00632
Abnormal spleen iron level 6.79×10−06 0.00765
Mitotic Anaphase 6.39×10−06 0.00765
Mitotic Metaphase and Anaphase 5.13×10−06 0.00765
Resolution of Sister Chromatid Cohesion 5.82×10−06 0.00765
Increased liver iron level 1.03×10−05 0.0103
Separation of Sister Chromatids 1.28×10−05 0.0115
Regulation of Rab GTPase activity 1.78×10−05 0.0123
Regulation of Rab protein signal transduction 1.78×10−05 0.0123
Protein phosphorylated amino acid binding 1.75×10−05 0.0123
Chromosome 2.57×10−05 0.0165
Hexosaminidase activity 3.47×10−05 0.0174
Abnormal learning memory conditioning 3.11×10−05 0.0174
Abnormal liver iron level 3.47×10−05 0.0174
Mitotic Prometaphase 2.99×10−05 0.0174
M Phase 3.70×10−05 0.0176
Positive regulation of Rab GTPase activity 5.93×10−05 0.0232
Rab GTPase activator activity 5.93×10−05 0.0232
Protein phosphatase type 2A regulator activity 5.24×10−05 0.0232
Replicative senescence 5.44×10−05 0.0232
Condensed nuclear chromosome 7.11×10−05 0.0267
Ubiquitin-specific protease activity 0.000104 0.0335
Ras GTPase activator activity 9.61×10−05 0.0335
Metabolism of porphyrins 0.000103 0.0335
Kinetochore 0.000103 0.0335
Decreased physiological sensitivity to xenobiotic 0.000127 0.0381
Antigen Activates B Cell Receptor Leading to Generation of Second Messengers 0.000124 0.0381
Phosphoprotein binding 0.000146 0.0424
Abnormal dorsal-ventral axis patterning 0.000152 0.0429
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